WallStreetZenWallStreetZen

NASDAQ: TVRD
Tvardi Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their TVRD stock forecasts and price targets.

Forecast return on equity

Is TVRD forecast to generate an efficient return?

Forecast return on assets

Is TVRD forecast to generate an efficient return on assets?

Company
-145.27%
Industry
36.11%
TVRD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TVRD earnings per share forecast

What is TVRD's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$4.08
Avg 2 year Forecast
-$3.84

TVRD revenue forecast

What is TVRD's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.1M-56.28%
Avg 2 year Forecast
$3.8M-47.46%
Avg 3 year Forecast
$25.2M+253.09%
TVRD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TVRD revenue growth forecast

How is TVRD forecast to perform vs Biotechnology companies and vs the US market?

Company
44.94%
Industry
63.02%
Market
10.2%
TVRD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TVRD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TVRD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TVRD$18.48N/AN/A
VIGL$1.81$16.33+802.38%Buy
GALT$1.34$11.00+720.90%Buy
CNTX$0.94$6.00+535.59%Strong Buy
ACHV$2.43$12.00+393.83%Strong Buy
View Top Biotech Stocks

Tvardi Therapeutics Stock Forecast FAQ

What is TVRD's earnings growth forecast for 2025-2026?

(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.73%.

Tvardi Therapeutics's earnings in 2025 is -$70,867,000.On average, 1 Wall Street analyst forecast TVRD's earnings for 2025 to be -$18,661,227, with the lowest TVRD earnings forecast at -$18,661,227, and the highest TVRD earnings forecast at -$18,661,227.

In 2026, TVRD is forecast to generate -$17,563,562 in earnings, with the lowest earnings forecast at -$17,563,562 and the highest earnings forecast at -$17,563,562.

If you're new to stock investing, here's how to buy Tvardi Therapeutics stock.

What is TVRD's revenue growth forecast for 2025-2027?

(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual revenue growth rate of 44.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.2%.

Tvardi Therapeutics's revenue in 2025 is $7,137,000.On average, 1 Wall Street analysts forecast TVRD's revenue for 2025 to be $14,269,651, with the lowest TVRD revenue forecast at $14,269,651, and the highest TVRD revenue forecast at $14,269,651. On average, 1 Wall Street analysts forecast TVRD's revenue for 2026 to be $17,151,023, with the lowest TVRD revenue forecast at $17,151,023, and the highest TVRD revenue forecast at $17,151,023.

In 2027, TVRD is forecast to generate $115,254,871 in revenue, with the lowest revenue forecast at $115,254,871 and the highest revenue forecast at $115,254,871.

What is TVRD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TVRD) forecast ROA is -145.27%, which is lower than the forecast US Biotechnology industry average of 36.11%.

What is TVRD's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: TVRD) Tvardi Therapeutics's current Earnings Per Share (EPS) is -$15.53. On average, analysts forecast that TVRD's EPS will be -$4.08 for 2025, with the lowest EPS forecast at -$4.08, and the highest EPS forecast at -$4.08. In 2026, TVRD's EPS is forecast to hit -$3.84 (min: -$3.84, max: -$3.84).

What is TVRD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TVRD) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.